CEVA Q1 2026 Earnings EPS Surprise Drives Positive Market Response Lixte Biotechnology Holdings Inc LIXT Q4 2024 Earnings Net Loss of 027 Per Share as Pipeline Progress Continues WHLRL Q2 2024 Earnings Unanticipated EPS Surge Amid Limited Disclosure CVEO Q1 2026 Earnings EPS Surprise of 45 Despite Negative Earnings BHVN Q1 2026 Earnings EPS Miss Amid Continued RD Investment Sagimet Biosciences Inc Q1 2026 Earnings Narrowed Loss Beats Expectations as Clinical Pipeline Advances